Investor Documents & Presentations
Annual Report & Accounts
General meeting documents
Results Presentations
- Interim Results for the 6 Months Period Ending 30th June 2021 – Presentation video
- Interim Results for the 6 Months Period Ending 30th June 2021 – Presentation slides
- Interim Results for the Period Ended 30 June 2021 and Business Update
- Business Update presentation 21 June 2021
- Preliminary Results for the 12 Months Period Ending 31st December 2020
- Preliminary Results for the year ending 31 December 2020 – Webinar presentation
- Preliminary Results for the 12 Months Period Ending 31st December 2020 – Presentation slides
- Interim Results for the 6 Month Period Ending 30th June 2020
- See more Results Presentations
Other Company Presentations and Videos
- FAP-Activated Drugs and Drug-Conjugates: Immunotherapy World Congress 2021
- preCISION / AVA6000 explained – CEO video presentation
- Business Update webinar – June 2021
- Video Q and A with Alastair Smith on licensing and partnering opportunities (March 2021)
- Video Q and A with Alastair Smith on Feb 2021 business update
- Alastair Smith discusses results of the initial evaluation of our SARS-CoV-2 lateral flow test with clinical samples
- Director's Talk interview: License agreement with Astrea Bioseparations
- Director’s talk interview: ‘Avacta Group make significant progress with its highly scalable lateral flow test’
- Alastair Smith gives SARS-CoV-2 Rapid Antigen Test video update
- How diagnostic test performance is measured
- Alastair Smith presents in Virtual Biotech Forum webinar
- How a Lateral Flow Rapid Test Works
- Alastair Smith provides overview of pre|CISION™ prodrug technology and update on AVA6000 clinical trial
- Alastair Smith provides update on AffyXell collaboration and licence agreement
- Alastair Smith provides update on TMAC programme
- An Investor’s Introduction to pre|CISION Chemotherapies
- See more company presentations
Research Notes
Other documents